Clinical Trials
26 trialsNCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT05568680 2026-05-12
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
Phase 1 Recruiting
NCT06251310 2026-05-08
SW-682 in Advanced Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06566079 2026-02-17
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT04525859 2025-06-24
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Oncovir, Inc.
Phase 1 Completed
NCT03917043 2025-06-18
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT03212404 2025-02-03
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Phase 1 Active not recruiting
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT06726564 2024-12-10
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1 Recruiting
NCT05228015 2024-11-18
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT06256055 2024-07-24
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Phase 1 Unknown
NCT05538572 2024-07-01
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
Phase 1 Completed
NCT05498597 2023-10-19
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT04042480 2023-03-23
A Study of SGN-CD228A in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT03507452 2023-03-20
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Bayer
Phase 1 Completed
NCT05698238 2023-03-15
CAMP1
Mabpro, a.s.
Phase 1 Not yet recruiting
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03852823 2021-04-30
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT00535951 2020-12-19
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Novartis
Phase 1 Completed
NCT01675765 2020-09-30
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Aduro Biotech, Inc.
Phase 1 Completed
NCT03920839 2020-04-24
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
Phase 1 Withdrawn
NCT02372227 2017-01-30
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Verastem, Inc.
Phase 1 Terminated